The Neutrophil-to-Lymphocyte Ratio Predicts Malignant Potential in Intraductal Papillary Mucinous Neoplasms

J Gastrointest Surg. 2015 Dec;19(12):2171-7. doi: 10.1007/s11605-015-2973-2. Epub 2015 Oct 6.

Abstract

Background: Accurately identifying malignant components in patients with pancreatic intraductal papillary mucinous neoplasms (IPMN) remains challenging. Preoperative neutrophil-to-lymphocyte ratio (NLR) is a marker of poor prognosis in patients with several types of malignancy. This study assessed whether NLR was predictive of intraductal papillary mucinous carcinoma (IPMC) in patients with IPMN.

Method: This study retrospectively assessed 76 patients who underwent curative resection for IPMN from 1995 to 2015. The correlation between the presence of malignant components and preoperative NLR was analyzed.

Results: Preoperative NLR in IPMC was significantly higher in patients with in IPMC (2.51 ± 0.84) than in patients with intraductal papillary mucinous adenoma (2.01 ± 0.71, P = 0.0079) and healthy volunteers (1.37 ± 0.33, P < 0.0001). NLR was significantly reduced after curative tumor resection. The main duct type (P = 0.0231) and NLR >2.074 (P = 0.0329) were independent predictors of IPMC in all patients. Combined criteria including international consensus guidelines, CA19-9 >37 IU/ml, and NLR >2.074 shows a high positive predictive value of 78 % and high specificity of 96 %.

Conclusions: Preoperative NLR is a useful supportive marker to predict IPMC in patients with IPMN.

Keywords: Intraductal papillary mucinous neoplasm; Malignant potential; Neutrophil-to-lymphocyte ratio.

MeSH terms

  • Adenocarcinoma, Mucinous / pathology
  • Aged
  • CA-19-9 Antigen
  • Carcinoma, Pancreatic Ductal / blood*
  • Carcinoma, Pancreatic Ductal / pathology*
  • Female
  • Humans
  • Leukocyte Count
  • Lymphocytes*
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neutrophils*
  • Pancreatic Neoplasms / blood*
  • Pancreatic Neoplasms / pathology*
  • Retrospective Studies
  • Sensitivity and Specificity

Substances

  • CA-19-9 Antigen